22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › VERTEX PHARMACEUTICALS INC. › 2024-2025

VERTEX PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and VERTEX PHARMACEUTICALS INC.’s Form 8-K, filed May 14, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 14Ballot items
  • 1,175Asset managers, any item
  • 16,693Fund votes
  • May 14, 2025Meeting date

Results at a glance

Meeting of May 14, 2025: 14 items on VERTEX PHARMACEUTICALS INC.’s Form 8-K, filed May 14, 2025: 2 approved · 11 passed (calculated) · 1 not approved.

Dissent

Significant dissent: 1 shareholder proposal (37.3% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore VERTEX PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by VERTEX PHARMACEUTICALS INC.

These tallies are VERTEX PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 14, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VERTEX PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 14, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Sangeeta Bhatia 224,220,1151,944,29377,828 --10,235,401 99.1%Passed (calculated)—
Elect Director: Lloyd Carney 217,229,0478,930,15083,039 --10,235,401 96%Passed (calculated)—
Elect Director: Alan Garber 222,204,6083,955,76481,864 --10,235,401 98%Passed (calculated)—
Elect Director: Reshma Kewalramani 225,606,258543,39892,580 --10,235,401 99.8%Passed (calculated)—
Elect Director: Michel Lagarde 223,304,0432,856,08082,113 --10,235,401 99%Passed (calculated)—
Elect Director: Jeffrey Leiden 220,817,1755,347,12277,939 --10,235,401 98%Passed (calculated)—
Elect Director: Diana McKenzie 224,648,1371,516,17477,925 --10,235,401 99.3%Passed (calculated)—
Elect Director: Bruce Sachs 211,582,89514,580,87578,466 --10,235,401 94%Passed (calculated)—
Elect Director: Jennifer Schneider 225,303,813859,65078,773 --10,235,401 99.6%Passed (calculated)—
Elect Director: Nancy Thornberry 223,303,1762,862,34476,716 --10,235,401 99%Passed (calculated)—
Elect Director: Suketu Upadhyay 224,313,8281,839,54288,866 --10,235,401 99.2%Passed (calculated)—
Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 229,386,0376,859,300232,300 --0 97%Approved—
Based upon the following votes, the shareholders approved, on an advisory basis, the 2024 compensation program for the Company's named executive officers 208,886,38617,048,300307,550 --10,235,401 92%Approved—
Based upon the following votes, the shareholders did not approve a shareholder proposal regarding excessive golden parachutes 84,117,100141,606,344518,792 --10,235,401 37%Not approved—

Source: VERTEX PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 14, 2025 — read the filing on EDGAR.

How asset managers voted at the VERTEX PHARMACEUTICALS INC. 2024-2025 meeting

1,175 asset managers disclosed a vote on at least one VERTEX PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Sangeeta Bhatia

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 224,220,115AGAINST: 1,944,293

Prior year: 99.6% for (May 15, 2024 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Sangeeta Bhatia

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Sangeeta Bhatia”): 224,220,115 for, 1,944,293 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 120,675,045 for, 20,150 against, 10,158 abstained, 1,636 not voted.

FOR
FOR: 120,675,045AGAINST: 20,150ABSTAIN: 10,158NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Sangeeta Bhatia” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3160 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,1360 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Elect Director: Lloyd Carney

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 217,229,047AGAINST: 8,930,150

Prior year: 96.2% for (May 15, 2024 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Lloyd Carney

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lloyd Carney”): 217,229,047 for, 8,930,150 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 117,395,530 for, 3,299,664 against, 10,158 abstained, 1,636 not voted.

FOR
FOR: 117,395,530AGAINST: 3,299,664ABSTAIN: 10,158NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Lloyd Carney” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3142 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street2,3363,198,800 00Against
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Elect Director: Alan Garber

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 222,204,608AGAINST: 3,955,764

Prior year: 99.4% for (May 15, 2024 meeting) ▼ 1.2 pts

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Alan Garber

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Alan Garber”): 222,204,608 for, 3,955,764 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 120,652,767 for, 42,427 against, 10,158 abstained, 1,636 not voted.

FOR
FOR: 120,652,767AGAINST: 42,427ABSTAIN: 10,158NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Alan Garber” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3151 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,1360 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Elect Director: Reshma Kewalramani

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 225,606,258AGAINST: 543,398

Prior year: 99.7% for (May 15, 2024 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Reshma Kewalramani

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Reshma Kewalramani”): 225,606,258 for, 543,398 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 120,688,357 for, 6,836 against, 10,159 abstained, 1,636 not voted.

FOR
FOR: 120,688,357AGAINST: 6,836ABSTAIN: 10,159NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Reshma Kewalramani” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3160 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,1360 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Elect Director: Michel Lagarde

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 223,304,043AGAINST: 2,856,080

Prior year: 99.9% for (May 15, 2024 meeting) ▼ 1.2 pts

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Michel Lagarde

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michel Lagarde”): 223,304,043 for, 2,856,080 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 120,688,181 for, 7,013 against, 10,158 abstained, 1,636 not voted.

FOR
FOR: 120,688,181AGAINST: 7,013ABSTAIN: 10,158NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Michel Lagarde” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3150 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,1360 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Elect Director: Jeffrey Leiden

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 220,817,175AGAINST: 5,347,122

Prior year: 98.1% for (May 15, 2024 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Jeffrey Leiden

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jeffrey Leiden”): 220,817,175 for, 5,347,122 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 120,587,324 for, 107,870 against, 10,158 abstained, 1,636 not voted.

FOR
FOR: 120,587,324AGAINST: 107,870ABSTAIN: 10,158NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Jeffrey Leiden” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3151 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,10630 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Elect Director: Diana McKenzie

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 224,648,137AGAINST: 1,516,174

Prior year: 98.3% for (May 15, 2024 meeting) ▲ 1.0 pts

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Diana McKenzie

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Diana McKenzie”): 224,648,137 for, 1,516,174 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 120,680,328 for, 14,866 against, 10,158 abstained, 1,636 not voted.

FOR
FOR: 120,680,328AGAINST: 14,866ABSTAIN: 10,158NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Diana McKenzie” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3160 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,1360 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Elect Director: Bruce Sachs

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 211,582,895AGAINST: 14,580,875

Prior year: 93.5% for (May 15, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Bruce Sachs

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bruce Sachs”): 211,582,895 for, 14,580,875 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 120,329,520 for, 365,675 against, 10,158 abstained, 1,636 not voted.

FOR
FOR: 120,329,520AGAINST: 365,675ABSTAIN: 10,158NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Bruce Sachs” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3142 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,06967 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Elect Director: Jennifer Schneider

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 225,303,813AGAINST: 859,650

Prior year: 99.9% for (May 15, 2024 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Jennifer Schneider

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jennifer Schneider”): 225,303,813 for, 859,650 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 120,669,899 for, 25,295 against, 10,158 abstained, 1,636 not voted.

FOR
FOR: 120,669,899AGAINST: 25,295ABSTAIN: 10,158NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Jennifer Schneider” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3160 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,1360 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Elect Director: Nancy Thornberry

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 223,303,176AGAINST: 2,862,344

Prior year: 99.9% for (May 15, 2024 meeting) ▼ 1.2 pts

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Nancy Thornberry

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Nancy Thornberry”): 223,303,176 for, 2,862,344 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 120,686,978 for, 8,216 against, 10,158 abstained, 1,636 not voted.

FOR
FOR: 120,686,978AGAINST: 8,216ABSTAIN: 10,158NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Nancy Thornberry” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3150 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,1360 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Elect Director: Suketu Upadhyay

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 224,313,828AGAINST: 1,839,542

Prior year: 99.7% for (May 15, 2024 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: Election of Directors: Suketu Upadhyay

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Suketu Upadhyay”): 224,313,828 for, 1,839,542 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 218 asset managers below reported 120,680,913 for, 14,280 against, 10,159 abstained, 1,636 not voted.

FOR
FOR: 120,680,913AGAINST: 14,280ABSTAIN: 10,159NOT VOTED: 1,636
Largest asset managers voting on “Election of Directors: Suketu Upadhyay” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,690,3160 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,1360 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 218 asset managers. All 218 are in the interactive database (link above).

Based upon the following votes, the shareholders approved, on an advisory basis, the 2024 compensation program for the…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 26 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%
FOR: 208,886,386AGAINST: 17,048,300

Prior year: 91.3% for (May 15, 2024 meeting) ▲ 1.1 pts

Details: description as filed, official tally, votes by 1,149 asset managers

Description as filed by funds: Advisory vote to approve named executive officer compensation.

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Based upon the following votes, the shareholders approved, on an advisory basis, the 2024 compensation program for the Company's named executive officers:”): 208,886,386 for, 17,048,300 against — passed, per its Form 8-K filed May 14, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 : Based upon the following votes, the shareholders approved, on an advisory basis, the 2024 compensation program for the Company's named executive officers:”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of VERTEX PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Section 14a Executive Compensation” (19 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “Compensation” (3 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “Say on pay” (2 managers, 788 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 210 asset managers voting on “Advisory vote to approve named executive officer compensation.” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,687,1563,160 00For
Fidelity10,514,7720 00For
BlackRock8,181,1104,112 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,200,513623 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,591,03610,499 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Fund voting reports, all 210 managers: 119,832,354 for, 728,766 against, 10,175 abstained, 1,636 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 976 asset managers voting on “Advisory vote to approve named executive officer compensation.” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group29,398,27556 00For
Capital Research Global Investors14,530,6080 00For
State Street7,426,514623 00For
Fidelity7,001,5150 00For
JPMorgan6,320,5120 00For
GEODE CAPITAL MANAGEMENT, LLC5,682,8080 00For
Wellington5,258,1830 00For
JENNISON ASSOCIATES LLC4,332,9845,224 00For
AllianceBernstein3,768,3370 00For
T. Rowe Price3,196,22030,591 00For
Loomis Sayles3,034,588107,618 00For
Janus Henderson2,572,3180 00For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/2,350,4050 00For
Northern Trust2,251,9760 00For
Charles Schwab1,726,2390 00For
Amundi01,685,423 00Against
Clearbridge Investments, LLC1,618,7810 00For
Vanguard1,599,1710 00For
Invesco1,575,3740 00For
Parnassus1,568,1020 00For
UBS01,348,803 00Against
MELLON INVESTMENTS Corp01,311,327 00Against
Union Investment Management GmbH01,260,519 00Against
EDGEWOOD MANAGEMENT LLC1,185,5960 00For
Legal & General Investment Management Ltd33,7101,146,626 00Against

Institutional-manager reports, all 976 managers: 134,333,986 for, 15,055,974 against, 179,756 abstained, 25,958 not voted, 56 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 229,386,037AGAINST: 6,859,300

Prior year: 98.3% for (May 15, 2024 meeting) ▼ 1.2 pts

Details: description as filed, official tally, votes by 224 asset managers

Description as filed by funds: Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2025.

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025:”): 229,386,037 for, 6,859,300 against — passed, per its Form 8-K filed May 14, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 224 asset managers below reported 120,554,106 for, 155,889 against, 13,362 abstained, 1,636 not voted.

FOR
FOR: 120,554,106AGAINST: 155,889ABSTAIN: 13,362NOT VOTED: 1,636
Largest asset managers voting on “Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending Decembe” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group33,698,7700 00For
Vanguard26,687,8662,450 00For
Fidelity10,514,7720 00For
BlackRock8,185,2220 00For
INVESTMENT CO OF AMERICA3,904,2100 00For
State Street3,201,06967 00For
AMCAP FUND2,869,4120 00For
JPMorgan2,714,4980 00For
Charles Schwab1,688,8110 00For
T. Rowe Price1,601,5350 00For
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND1,425,7300 00For
Parnassus1,409,3510 00For
Columbia Threadneedle1,305,9180 00For
NEW ECONOMY FUND1,282,9740 00For
MFS1,263,9310 00For
Prudential/PGIM1,104,8930 00For
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 224 asset managers. All 224 are in the interactive database (link above).

Based upon the following votes, the shareholders did not approve a shareholder proposal regarding excessive golden…

Official resultCOMPENSATIONReported outcome: Not approved

Combines 10 wordings of this item as funds reported it.

37% Not approved · of votes cast

FOR 37%AGAINST
FOR: 84,117,100AGAINST: 141,606,344
Details: description as filed, official tally, votes by 254 asset managers

Description as filed by funds: Shareholder proposal, if properly presented at the meeting, regarding excessive golden parachutes.

VERTEX PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: Based upon the following votes, the shareholders did not approve a shareholder proposal regarding excessive golden parachutes:”): 84,117,100 for, 141,606,344 against — failed, per its Form 8-K filed May 14, 2025 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “Proposal No. 4: Based upon the following votes, the shareholders did not approve a shareholder proposal regarding excessive golden parachutes:”
Support: 37% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 254 asset managers below reported 21,953,464 for, 98,540,815 against, 10,224 abstained, 1,636 not voted, 50 unknown.

FORAGAINST
FOR: 21,953,464AGAINST: 98,540,815ABSTAIN: 10,224NOT VOTED: 1,636UNKNOWN: 50
Largest asset managers voting on “Shareholder proposal, if properly presented at the meeting, regarding excessive golden parachutes.” at VERTEX PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group033,698,770 00Against
Vanguard4,265,26122,425,055 00Mixed
Fidelity122,06410,392,708 00Against
BlackRock18,8168,166,406 00Against
INVESTMENT CO OF AMERICA03,904,210 00Against
State Street1,8083,199,328 00Against
AMCAP FUND02,869,412 00Against
JPMorgan02,714,498 00Against
Charles Schwab01,688,811 00Against
T. Rowe Price01,601,535 00Against
JANUS INVESTMENT FUND1,505,9470 00For
Victory Capital1,477,1740 00For
ADVISORS' INNER CIRCLE FUND01,425,730 00Against
Parnassus1,409,3510 00For
Columbia Threadneedle01,305,918 00Against
NEW ECONOMY FUND01,282,974 00Against
MFS01,263,931 00Against
Prudential/PGIM1,030,76274,131 00Mixed
Loomis Sayles978,5400 00For
TIAA957,5470 00For
HARBOR FUNDS954,1590 00For
AB LARGE CAP GROWTH FUND INC644,1740 00For
Legg Mason589,9370 00For
Invesco569,6850 00For
Hartford553,7260 00For

Showing the 25 largest of 254 asset managers. All 254 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of May 15, 2024, which belongs to the 2023-2024 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest VERTEX PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 256,967,767 shares outstanding at the time of that meeting.

Fund voting reports: top VERTEX PHARMACEUTICALS INC. shareholders by shares voted on “Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year…”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 13.11%
2Vanguard 10.39%
3Fidelity 4.09%
4BlackRock 3.19%
5INVESTMENT CO OF AMERICA 1.52%
6State Street 1.25%
7AMCAP FUND 1.12%
8JPMorgan 1.06%
9Charles Schwab 0.66%
10T. Rowe Price 0.62%
Institutional-manager reports: top VERTEX PHARMACEUTICALS INC. shareholders by shares voted on “Advisory vote to approve named executive officer compensation.”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 11.44%
2Capital Research Global Investors 5.65%
3State Street 2.89%
4Fidelity 2.72%
5JPMorgan 2.46%
6GEODE CAPITAL MANAGEMENT, LLC 2.21%
7Wellington 2.05%
8JENNISON ASSOCIATES LLC 1.69%
9AllianceBernstein 1.47%
10T. Rowe Price 1.26%

Reported VERTEX PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

VERTEX PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Capital World Investors25,695,015 10.00%Schedule 13G, filed May 14, 2026
The Vanguard Group22,281,729 8.67%Proxy statement (DEF 14A), proxy filed April 3, 2025
BlackRock21,782,933 8.48%Form 13F, quarter ended March 31, 2025
Capital Research Global Investors21,139,169 8.23%Schedule 13G, filed May 14, 2026
State Street11,788,657 4.59%Form 13F, quarter ended March 31, 2025
JPMorgan Chase7,755,645 3.02%Form 13F, quarter ended March 31, 2025
FMR (Fidelity)7,727,184 3.01%Form 13F, quarter ended March 31, 2025
Wellington Management5,454,748 2.12%Form 13F, quarter ended March 31, 2025
Norges Bank3,457,950 1.35%Form 13F, quarter ended March 31, 2025
Morgan Stanley3,408,520 1.33%Form 13F, quarter ended March 31, 2025

Percentages above are of 256,967,767 shares outstanding, as reported by VERTEX PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At VERTEX PHARMACEUTICALS INC.'s shareholder meeting held May 14, 2025, in the 2024-2025 proxy season, 1,175 asset managers reported votes on at least one of its 14 ballot items in their SEC Form N-PX filings, covering 16,693 separate fund positions. On the most widely held item on that ballot — Advisory vote to approve named executive officer compensation. — VERTEX PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: VERTEX PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 14, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VERTEX PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

VERTEX PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “VERTEX PHARMACEUTICALS (VRTX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/vertex-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.